Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Louis H. Weimer, MD, Columbia University
ClinicalTrials.gov Identifier:
NCT01378546
First received: June 20, 2011
Last updated: July 17, 2013
Last verified: July 2013
  Purpose

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells.

3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.


Condition Intervention
Lambert Eaton Myasthenic Syndrome (LEMS)
Drug: 3,4-diaminopyridine

Study Type: Expanded Access     What is Expanded Access?
Official Title: Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine

Resource links provided by NLM:


Further study details as provided by Columbia University:

Study Start Date: May 2005
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: 3,4-diaminopyridine
    Treatment will begin with 5mg three times a day or less.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be diagnosed with LEMS or a type of CMS likely to respond to 3, 4-DAP.
  • If female of childbearing age, have negative pregnancy test, and be willing to practice and effective form of birth control during the study.
  • Tested and found by ECG not to have a prolonged QTc syndrome.
  • Agrees to have a second ECG at the time of peak drug effect. Has understood and signed the Informed Consent.

Exclusion Criteria:

  • Is known to have a sensitivity to 3, 4-DAP.
  • Has a history of past or current seizures or of severe asthma, or has an epileptiform EEG.
  • Is believed by the investigator to be unable to comply with the protocol.
  • Is unable to give informed consent.
  • No patient will be excluded based on race, ethnicity, gender, or HIV status
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01378546

Locations
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Louis H. Weimer, MD
Investigators
Principal Investigator: Louis H Weimer, MD Columbia University
  More Information

No publications provided

Responsible Party: Louis H. Weimer, MD, Clinical Professor of Neurology, Columbia University
ClinicalTrials.gov Identifier: NCT01378546     History of Changes
Other Study ID Numbers: AAAB2528
Study First Received: June 20, 2011
Last Updated: July 17, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lambert-Eaton Myasthenic Syndrome
Myasthenic Syndromes, Congenital
Syndrome
Paraneoplastic Syndromes
Paraneoplastic Syndromes, Nervous System
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Disease
Genetic Diseases, Inborn
Immune System Diseases
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Neurodegenerative Diseases
Neuromuscular Diseases
Neuromuscular Junction Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 20, 2014